stockportfolio.pro
Stocks / NEO vs NVAX
NEO vs NVAX
NeoGenomics, Inc. and Novavax, Inc. side by side — fundamentals from SEC filings, refreshed nightly. Sector: Healthcare.
| NeoGenomics, Inc. (NEO) | Novavax, Inc. (NVAX) | |
|---|---|---|
| Market cap | $1.5B | $1.4B |
| Revenue (latest FY) | $727.33M | $1.12B |
| Net income (latest FY) | $-108.03M | $440.30M |
| Revenue growth (5y CAGR) | 10.4% | 18.8% |
| Net margin | -14.9% | 39.2% |
| Return on equity | -12.9% | -344.7% |
| P/E ratio | — | — |
| Dividend yield | — | — |
| Profitable years (of last 10) | 3 | 1 |
| Positive free cash flow | No | No |
Compare them properly — statement by statement
Open either company interactively: 19 years of income statement, balance sheet and cash flow, ratios, health checks, and Ask — the SEC-grounded research assistant.
Open NEO — free Open NVAX — freeFrequently asked questions
Which is bigger, NEO or NVAX?
NeoGenomics, Inc. is larger by market capitalization — $1.5B versus $1.4B.
Which grows faster, NEO or NVAX?
Over the last five fiscal years, Novavax, Inc. grew revenue faster — 18.8%/yr versus 10.4%/yr, computed from SEC-filed statements.
Where does this data come from?
All figures are computed from official SEC filings (10-K), refreshed nightly. This is a data comparison, not investment advice.